Merck & Co., Inc.'s Q3 earnings report is anticipated on 31st October — next Thursday. Despite strong Q2 performance, Merck's stock fell due to a guidance downgrade related to issues with key ...

Despite Merck & Co. homing in on approval for its infant respiratory syncytial virus (RSV) antibody clesrovimab, Sanofi—which last year won its own nod for its AstraZeneca-partnered RSV ...

Merck’s acquisition of Modifi Biosciences will give it access to preclinical cancer drug candidates that target DNA repair processes. Modifi Biosciences, a spin out of Yale University founded in 2021, ...

Oct. 23, 2024 (GLOBE NEWSWIRE) -- Modifi Biosciences, Inc. (“Modifi Biosciences”), a leader in the development of direct DNA modification enabled cancer therapeutics, today announced that the company ...

In a 14-1 vote, the panel moved to expand its usage recommendation for both Pfizer’s Prevnar 20 and Merck’s Capvaxive to include all adults aged 50 and older as well as adults between 19 and ...

Oct 23 (Reuters) - Merck (MRK.N), opens new tab has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the privately held biotech firm ...

Merck & Co. is putting down $30 million upfront to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset designed to take on the tough-to-treat brain cancer glioblastoma (GBM).

(Reuters) - Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the privately held biotech firm said on Wednesday. As part of ...

“We are honored to have Merck recognize the potential of our science, and as an oncology company, they are perfectly positioned to advance our innovations through clinical trials and ...

Today, a brief rundown of news from Merck & Co. and Roche, as well as updates from Sangamo Therapeutics, UCB and Catalent that you may have missed. MacroGenics, a developer of antibody medicines for ...

Gilead Sciences and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to sustained suppression of the virus out to 48 weeks in a ...